Literature DB >> 26750756

Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis.

Ling Lei1, Cheng Zhao1, Fang Qin1, Zhi-Yi He2, Xu Wang1, Xiao-Ning Zhong2.   

Abstract

OBJECTIVES: Systemic sclerosis (SSc) is characterised by fibrosis of the skin and internal organs, such as the lungs. Enhanced Th17 responses are associated with skin fibrosis in patients with SSc, however, whether they are associated with lung fibrosis has not been clarified. This study aimed to investigate the potential association of Th17 responses with the skin and pulmonary fibrosis as well as the potential mechanisms in a mouse bleomycin (BLM) model of SSc.
METHODS: BALB/c mice were injected subcutaneously with phosphate buffered saline (PBS) (control) or BLM for 28 days and the skin and pulmonary inflammation and fibrosis were characterized by histology. The percentages of circulating, skin and pulmonary infiltrating Th17 cells and the contents of collagen in mice were analysed. The levels of RORγt, IL-17A, IL-6 and TGF-β1 mRNA transcripts in the skin and lungs were determined by quantitative RTPCR and the levels of serum IL-17A, IL-6 and TGF-β1 were determined by ELISA. Furthermore, the effect of rIL-17A on the proliferation of pulmonary fibroblasts and their cytokine expression was analysed. The potential association of Th17 responses with the severity of skin and lung fibrosis was analysed.
RESULTS: In comparison with the control mice, significantly increased skin and pulmonary inflammation and fibrosis and higher levels of hydroxyproline were detected in the BLM mice. Significantly higher frequency of circulating, skin and lung infiltrating Th17 cells and higher levels of serum, skin and lung IL-17A, TGF-β1, IL-6 and RORγt were detected in the BLM mice. The concentrations of serum IL-17A were correlated positively with the percentages of Th17 cells and the contents of skin hydroxyproline in the BLM mice. The levels of IL-17A expression were positively correlated with the skin and lung inflammatory scores as well as the skin fibrosis in the BLM mice. In addition, IL-17A significantly enhanced pulmonary fibroblast proliferation and their type I collagen, TGF-β and IL-6 expression in vitro, which were attenuated by treatment with anti-IL-17A.
CONCLUSIONS: Our results indicate that Th17 cells participate in the pathogenesis of skin and lung fibrosis by enhancing fibroblast proliferation and cytokine production in a mouse BLM model of SSc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26750756

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  37 in total

Review 1.  Interleukin-17: Friend or foe in organ fibrosis.

Authors:  Kritika Ramani; Partha S Biswas
Journal:  Cytokine       Date:  2019-02-14       Impact factor: 3.861

2.  Higher levels of serum interleukin-35 are associated with the severity of pulmonary fibrosis and Th2 responses in patients with systemic sclerosis.

Authors:  Jie Tang; Ling Lei; Jie Pan; Cheng Zhao; Jing Wen
Journal:  Rheumatol Int       Date:  2018-05-30       Impact factor: 2.631

3.  Involvement of IL-17 in Secondary Brain Injury After a Traumatic Brain Injury in Rats.

Authors:  Tan Li; Yong-Mei Zhang; Dong Han; Rong Hua; Bing-Nan Guo; Shu-Qun Hu; Xian-Liang Yan; Tie Xu
Journal:  Neuromolecular Med       Date:  2017-09-15       Impact factor: 3.843

Review 4.  Interleukin-17 pathways in systemic sclerosis-associated fibrosis.

Authors:  Sakir Ahmed; Durga Prasanna Misra; Vikas Agarwal
Journal:  Rheumatol Int       Date:  2019-05-09       Impact factor: 2.631

5.  Elevated levels of TL1A are associated with disease activity in patients with systemic sclerosis.

Authors:  Wangdong Xu; Linchong Su; Pingying Qing; Ying Wang; Yan Liang; Yi Zhao; Qiongxiu Zhou; Feng Ma; Yi Liu
Journal:  Clin Rheumatol       Date:  2017-04-10       Impact factor: 2.980

6.  Correlations Between Clinical Features and Mouth Opening in Patients With Systemic Sclerosis.

Authors:  İpek TÜrk; Nihan CÜzdan; Volkan ÇİftÇİ; Didem Arslan; İlker Ünal
Journal:  Arch Rheumatol       Date:  2020-02-07       Impact factor: 1.472

Review 7.  What can we learn from Fli1-deficient mice, new animal models of systemic sclerosis?

Authors:  Yoshihide Asano
Journal:  J Scleroderma Relat Disord       Date:  2018-04-04

8.  Based on network pharmacology and in vitro experiments to prove the effective inhibition of myocardial fibrosis by Buyang Huanwu decoction.

Authors:  Tianyue Wang; Xinyu Jiang; Yanmin Ruan; Jun Zhuang; Yuanjun Yin
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

9.  Genetic Adjuvantation of a Cell-Based Therapeutic Vaccine for Amelioration of Chagasic Cardiomyopathy.

Authors:  Vanaja Konduri; Matthew M Halpert; Dan Liang; Jonathan M Levitt; Julio Vladimir Cruz-Chan; Bin Zhan; Maria Elena Bottazzi; Peter J Hotez; Kathryn M Jones; William K Decker
Journal:  Infect Immun       Date:  2017-08-18       Impact factor: 3.441

10.  Autoimmunity and Cytokine Imbalance in Inherited Epidermolysis Bullosa.

Authors:  Susanna Esposito; Sophie Guez; Annalisa Orenti; Gianluca Tadini; Giulietta Scuvera; Laura Corti; Alessia Scala; Elia Biganzoli; Emilio Berti; Nicola Principi
Journal:  Int J Mol Sci       Date:  2016-09-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.